CTOs on the Move

Quanterix

www.quanterix.com

 
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company`s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix` technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.quanterix.com
  • 900 Middlesex Turnpike
    Billerica, MA USA 01821
  • Phone: 617.301.9400

Executives

Name Title Contact Details
Joel Nichols
Senior Vice President Digital and Information Profile

Funding

Quanterix raised $46M on 03/23/2016
Quanterix raised $49.7M on 10/25/2019
Quanterix raised $287.5M on 02/08/2021

Similar Companies

BioComm Network

BioComm Network is a Laguna Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SimBioSys Inc

SimBioSys Inc is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SpIntellx

See More. Know More. Power Precision Pathology.

NantKwest

NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

Obsidian Therapeutics

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian`s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we`re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge, we`re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.